COVID-19
Targeting Covid-19 prophylactics, therapeutics and vaccines to mucosal surfaces
Why NovochizolTM ?
- Mucoadherence in the airways and the digestive tract
- Intra-pulmonary drug delivery reaching all lung epithelia
- Localized pharmacokinetics, without systemic distribution
- Sustained release
- Adjuvant properties for intra-nasal vaccines
- Ideal carrier fror multi-epitope intranasal vaccines
- Nine Covid-19 drug candidates formulated as aerosols
Research and Development
Aerosol formulation of Bivalent Human VH Domains against multiple SARS-Cov-2 Spike variants
A collaborative research project with the Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School.
SARS-CoV-2 spike receptor binding domain intranasal vaccine formulation
A collaborative research project with the Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School.
Mucosal vaccines against COVID-19: open collaboration
Novochizol™ allows to address the main challenge in developing the ultimate COVID-19 vaccine: finding the right combination of antigens to elicit sterilizing mucosal immunity, leading to virus eradication.
Novochizol TM-Losartan aerosol formulation preclinical safety
On March 19,2020 we conducted an urgent pre-clinical animal safety assessment by administering to a swine Losartan-N aerosol, delivering approximately 270 micrograms of active ingredient over a period of 30 minutes.
